SCHEMBL810376

SCHEMBL810376

COc1cccc(Sc2cc(C)cc(N)c2)c1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.49
CYP3A4 P08684 1/20 0.49
ACHE P22303 1/20 0.46
DHFR P00374 7/20 0.45
EGFR P00533 1/20 0.44
PDGFRB P09619 1/20 0.44
KDR P35968 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.42
MTNR1A P48039 1/20 0.41
MTNR1B P49286 1/20 0.41
HTR1A P08908 1/20 0.41
HTR3A P46098 1/20 0.41
PTGIR P43119 1/20 0.40
CYP19A1 P11511 1/20 0.40
ABCG2 Q9UNQ0 1/20 0.39
IDO1 P14902 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7183466 0.83 ALDH1A1 (0.46) ALDH1A1CYP3A4ACHEHTR1AHTR3A
SCHEMBL810653 0.82 PTGIR (0.47) ALDH1A1CYP3A4ACHEDHFRSMN1; SMN2
SCHEMBL31425668 0.81 ACHE (0.54) ALDH1A1CYP3A4ACHEDHFRMTNR1A
SCHEMBL3164341 0.81 ACHE (0.54) ALDH1A1CYP3A4ACHEDHFRMTNR1A
SCHEMBL24433577 0.79 ACHE (0.52) ALDH1A1CYP3A4ACHEDHFRMTNR1A
SCHEMBL31345530 0.78 ACHE (0.53) ACHEDHFREGFRPDGFRBKDR
SCHEMBL3484059 0.78 ACHE (0.53) ACHEDHFREGFRPDGFRBKDR
SCHEMBL10709610 0.77 MTNR1A (0.57) ALDH1A1CYP3A4ACHEDHFRMTNR1A
SCHEMBL7187600 0.77 ALDH1A1 (0.63) ALDH1A1CYP3A4ACHESMN1; SMN2IDO1
SCHEMBL13163776 0.76 EDNRA (0.54) ALDH1A1CYP3A4ACHEDHFRMTNR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971611-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2012-10-10 EP disclosed
EP-2345652-A1 Antiviral compounds Abbott Laboratories (US) 2011-07-20 EP disclosed
US-7915411-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2011-03-29 US disclosed
EP-1971611-A1 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-09-24 EP disclosed
US-20070197558-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-08-23 US disclosed
WO-2007081517-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197558-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 ALDH1A1 2723/4885CYP3A4 273/4885ACHE 3889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.